Navigation Links
Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics

A Complimentary Webinar

MOUNTAIN VIEW, Calif., March 30 /PRNewswire/ --

     -  TOPIC:      The state of the microRNA market and the molecule's
                    current and potential impact on drug discovery, molecular
                    diagnostics, and personalized therapeutics.
     -  WHEN:       Tuesday, March 31, 2009
     -  TIME:       3 pm EDT
     -  LOCATION:   Online with free registration
     -  HOST:       Christi Bird, Senior Research Analyst, Healthcare
                    practice, Frost & Sullivan
     -  GUESTS:
          -  Dr. George Calin, Associate Professor, The University of Texas
             M. D. Anderson Cancer Center
          -  Alex Amiet, Senior Product Manager, Thermo Fisher Scientific

     -  This panel discussion will benefit life science research tools
        manufacturers, services providers, diagnostic companies,
        biotechnology companies, pharmaceutical companies, academic
        researchers and venture capitalists.  The outlook for the microRNA
        market will be presented from a three-pronged perspective of an
        industry analyst with knowledge of the market, a microRNA expert
        from academia, and a provider of microRNA tools and services.

Supporting Quote

"The rapid discoveries linking microRNAs to various diseases have propelled the microRNA field and tools market in recent years. Moving forward, however, the microRNA field requires more innovative studies of larger scope to make good on its lofty promise," says Bird of Frost & Sullivan.

Supporting Resources

To participate, please email Stephanie Ochoa,, with the following information: your full name, title, company name, company telephone number, company email address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Frost & Sullivan's Drug Discovery practice:

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Stephanie Ochoa
    Frost & Sullivan


SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
2. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
3. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
4. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
5. Frost & Sullivan: In Vitro Diagnostics Market
6. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
7. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
8. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
9. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
10. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
11. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
Breaking Biology News(10 mins):